Abstract:The elderly are at a much higher risk of atherosclerostic cardiovascular disease (ASCVD), while dyslipidemia is reported as an independent risk factor for ASCVD. Management of dyslipidemia, especially cholesterol-lowering therapy, exerts significant effect on the primary and secondary prevention for ASCVD with a good safety profile in the elderly. On the basis of improving lifestyle, statin is a prior choice for the management of dyslipidemia. Personalized therapeutic strategy for the elderly should include proper initial dosage of lipid-lowering drug according to the lipid levels and ASCVD risk stratification, and then titration of the dosage based on response to therapy for the purpose of reaching low-density lipoprotein cholesterol (LDL-C) target as the same as to young people.